ÂÜÀòÂÒÂ×

David Rooklin is the CEO of Redesign Science. David was previously a research intern at Merck in the Cardiovascular Disease Department, where they did gene network analysis to identify potential drug targets to treat atherosclerosis and hypertension. David was also a research associate at New York University, where they did drug design, software development, and entrepreneurship. David was also a research technician at the University of Colorado at Boulder in the Josef Michl Lab, where they did quantum calculation and molecular orbital analysis.

David Rooklin received their Bachelor's degree in Biochemistry from Oberlin College and their Doctor of Philosophy (Ph.D.) in Computational Biology from New York University.

Some individuals on their team include Haotian Li - CTO, Andrew Avorn - General Counsel, and Artavazd Arumov - Business Development Lead.